Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 29446853)

  • 1. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
    Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
    Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
    Nakamura K; Taguchi E; Miura T; Yamamoto A; Takahashi K; Bichat F; Guilbaud N; Hasegawa K; Kubo K; Fujiwara Y; Suzuki R; Kubo K; Shibuya M; Isae T
    Cancer Res; 2006 Sep; 66(18):9134-42. PubMed ID: 16982756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
    McCarty MF; Wey J; Stoeltzing O; Liu W; Fan F; Bucana C; Mansfield PF; Ryan AJ; Ellis LM
    Mol Cancer Ther; 2004 Sep; 3(9):1041-8. PubMed ID: 15367698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP.
    Budd S; Byfield G; Martiniuk D; Geisen P; Hartnett ME
    Exp Eye Res; 2009 Nov; 89(5):718-27. PubMed ID: 19576214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.
    Sun Q; Zhou J; Zhang Z; Guo M; Liang J; Zhou F; Long J; Zhang W; Yin F; Cai H; Yang H; Zhang W; Gu Y; Ni L; Sai Y; Cui Y; Zhang M; Hong M; Sun J; Yang Z; Qing W; Su W; Ren Y
    Cancer Biol Ther; 2014; 15(12):1635-45. PubMed ID: 25482937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
    Wedge SR; Kendrew J; Hennequin LF; Valentine PJ; Barry ST; Brave SR; Smith NR; James NH; Dukes M; Curwen JO; Chester R; Jackson JA; Boffey SJ; Kilburn LL; Barnett S; Richmond GH; Wadsworth PF; Walker M; Bigley AL; Taylor ST; Cooper L; Beck S; J├╝rgensmeier JM; Ogilvie DJ
    Cancer Res; 2005 May; 65(10):4389-400. PubMed ID: 15899831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells.
    Young E; Miele L; Tucker KB; Huang M; Wells J; Gu JW
    Cancer Biol Ther; 2010 Oct; 10(7):703-11. PubMed ID: 20686367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herbal compound farnesiferol C exerts antiangiogenic and antitumor activity and targets multiple aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1) signaling cascades.
    Lee JH; Choi S; Lee Y; Lee HJ; Kim KH; Ahn KS; Bae H; Lee HJ; Lee EO; Ahn KS; Ryu SY; L├╝ J; Kim SH
    Mol Cancer Ther; 2010 Feb; 9(2):389-99. PubMed ID: 20103598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D; Tang F; Wang S; Jiang Z; Zhang L
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CM082, a novel VEGF receptor tyrosine kinase inhibitor, can inhibit angiogenesis in vitro and in vivo.
    Dan H; Lei X; Huang X; Ma N; Xing Y; Shen Y
    Microvasc Res; 2021 Jul; 136():104146. PubMed ID: 33610563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
    Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D
    Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR.
    Zhou Y; Chen Y; Tong L; Xie H; Wen W; Zhang J; Xi Y; Shen Y; Geng M; Wang Y; Jiang H; Luo C; Lin L; Ding J
    J Cell Mol Med; 2012 Oct; 16(10):2321-30. PubMed ID: 22304225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.
    Pang X; Yi Z; Zhang X; Sung B; Qu W; Lian X; Aggarwal BB; Liu M
    Cancer Res; 2009 Jul; 69(14):5893-900. PubMed ID: 19567671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
    Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
    Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation.
    Mu X; Shi W; Sun L; Li H; Jiang Z; Zhang L
    Molecules; 2012 Jun; 17(6):6854-68. PubMed ID: 22669041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.